Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1629

Sort by

Sort Order Select

Journal Articles

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Katarzyna Aleksandra Jalowiec, Thomas Pabst, MD, Christoph Bocksrucker, Claudio Brunold, Barbara Jeker, Gabriela M Baerlocher, MD, Urban Novak, Ulrike Bacher, Michael Daskalakis, MD, Behrouz Mansouri, MD, Sacha S Zeerleder, MD PhD

Blood (2019) 134 (Supplement_1): 2457.

https://doi.org/10.1182/blood-2019-126534

Published: 2019

Journal Articles

Disease Modeling of Severe Congenital Neutropenia Using CRISPR/Cas9 Gene Correction or Knockout of ELANE in Patients Derived Induced Pluripotent Stem Cells

Masoud Nasri, MSc, Benjamin Dannenmann, Perihan Mir, Malte U Ritter, Diana Amend, Yun Xu, Maksim Klimiankou, Cornelia Zeidler, Karl Welte, Julia Skokowa, MD PhD

Blood (2019) 134 (Supplement_1): 434.

https://doi.org/10.1182/blood-2019-129991

Published: 2019

Journal Articles

CRISPR/Cas9 Mediated ELANE Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensible Granulocyte Protease?

Vahagn Makaryan, MD, Isabella N. Archibald, Merideth L. Kelley, MS, Breanna Fletcher, BSc, David C. Dale, MD

Blood (2019) 134 (Supplement_1): 435.

https://doi.org/10.1182/blood-2019-124988

Published: 2019

Journal Articles

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

Max Yano, Jennie Rachel Lance, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4302.

https://doi.org/10.1182/blood-2019-127620

Published: 2019

Journal Articles

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Jennie Rachel Lance, Max Yano, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4303.

https://doi.org/10.1182/blood-2019-131034

Published: 2019

Journal Articles

Role of Acute Myeloid Leukemia Derived-Extracellular Vesicles in Dysregulating Normal Hematopoiesis

Ilaria Laurenzana, PhD, Stefania Trino, PhD, Daniela Lamorte, PhD, Michele Santodirocco, MD, Lazzaro Di Mauro, MD, Borazio Nazario, Antonella Caivano, Luciana De Luca, Pellegrino Musto, MD

Blood (2019) 134 (Supplement_1): 1411.

https://doi.org/10.1182/blood-2019-125544

Published: 2019

Journal Articles

Night Transplantation and Catecholamine Exposure Accelerates In Vivo Leukemia Development By Enhancing Bone Marrow Homing Capacity in Leukemic Cells

Pauline Hanns, MSc, Anna M Paczulla, PhD, Martina Konantz, PhD, Marcelle Baer, MSc, Pontus Lundberg, PhD, Stefan Dirnhofer, MD, Claudia Lengerke, MD

Blood (2019) 134 (Supplement_1): 1446.

https://doi.org/10.1182/blood-2019-126984

Published: 2019

Journal Articles

Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)

Matthew C Foster, MD, Yuri Fedoriw, MD, Will Pulley, BA, Joshua Zeidner, MD, Catherine C. Coombs, MD, Emily Mirkin, Maryam Zomorrodi, Rachel Toughiri, PhD, Alena Bartakova, MD, Craig Carson, PhD, Rolf Muller, PhD, Paul M. Armistead, MD PhD

Blood (2019) 134 (Supplement_1): 1417.

https://doi.org/10.1182/blood-2019-127434

Published: 2019

Journal Articles

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Christina Maria Zeller, MSc, Daniel Richter, MSc, Binje Vick, PhD, Tobias Herold, MD, Johannes Bagnoli, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Wolfgang Enard, PhD, Irmela Jeremias, MD PhD

Blood (2019) 134 (Supplement_1): 1450.

https://doi.org/10.1182/blood-2019-127867

Published: 2019

Journal Articles

Combination of a Cyclophosphamide-Total Body Irradiation Conditioning Regimen and Tacrolimus Plus Mycophenolate Mofetil for Gvhd Prophylaxis Is Associated with Higher HHV-6 Encephalitis Incidence after Cord Blood Transplantation

Takuto Mori, MD, Nobuhiro Hiramoto, MD, Ryosuke Ueda, MD PhD, Yoshimitsu Shimomura, Satoshi Yoshioka, MD PhD, Takayuki Ishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1986.

https://doi.org/10.1182/blood-2019-125209

Published: 2019

Journal Articles

Are We Choosing Mobilization Regimens for Autologous Stem Cell Transplantation in Multiple Myeloma Wisely?: A Single Centre Comparison of GCSF+/-Plerixafor Vs Cyclophosphamide/GCSF+/- Plerixafor

Chloe Yang, MD, Mina Dehghani, MD, Wilma Hopman, MSc, Sita D. Bhella, MD

Blood (2019) 134 (Supplement_1): 2136.

https://doi.org/10.1182/blood-2019-128819

Published: 2019

Journal Articles

Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations

Sandhya R. Panch, MDMPH, Brent R. Logan, Jennifer A. Sees, MPH, Bipin N. Savani, MD, Nirali N. Shah, MD, Jack W. Hsu, MD, Michael A. Pulsipher, MD, Galen E. Switzer, PhD, Bronwen E. Shaw, MD PhD, David F. Stroncek, MD

Blood (2019) 134 (Supplement_1): 1962.

https://doi.org/10.1182/blood-2019-123492

Published: 2019

Journal Articles

Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor

Alexis Leonard, MD, Naoya Uchida, MD, David F. Stroncek, MD, Sandhya R. Panch, MDMPH, Kamille West, Eoghan George Molloy, MD, Tom Hughes, Pharm.D., Sara Hauffe, RN, Tiffani Taylor, Courtney D. Fitzhugh, MD, Jane S. Hankins, MD MS, Megan Wilson, MSW, CCRP, Akshay Sharma, MBBS, Shengdar Q. Tsai, PhD, Mitchell J. Weiss, MD, PhD, Matthew Hsieh, MD, John F. Tisdale, MD

Blood (2019) 134 (Supplement_1): 1964.

https://doi.org/10.1182/blood-2019-126091

Published: 2019

Journal Articles

Protein Arginine Methyltransferase 1 Is Required for Maintenance of Normal Adult Hematopoiesis

Lei Zhu, MD, Xin He, PhD, Haojie Dong, PhD, Jie Sun, PhD, Hanying Wang, PhD, Yinghui Zhu, PhD, Feiteng Huang, Jingying Zou, Xiaoying Zhao, MD, Ling Li, PhD

Blood (2019) 134 (Supplement_1): 3708.

https://doi.org/10.1182/blood-2019-126050

Published: 2019

Journal Articles

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Carsten Riether, PhD, Tanja Chiorazzo, PhD, Amy J. Johnson, PhD, Christina Diane Drenberg, PhD, Khaja Waheeduddin Syed, BPharm, MS, Mahan Moshir, MSc, Anna Hultberg, PhD, Nicolas Leupin, Hans De Haard, Adrian F Ochsenbein, MD

Blood (2019) 134 (Supplement_1): 3918.

https://doi.org/10.1182/blood-2019-127464

Published: 2019

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum

Blood (2019) 134 (Supplement_1): 4078.

https://doi.org/10.1182/blood-2019-124297

Published: 2019

Journal Articles

Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation

Cindy Lynn Hickey, MDFRCPC, Haesook T. Kim, PhD, Sarah Nikiforow, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Jerome Ritz, MD, Vincent T. Ho, MD, Edwin P. Alyea, III, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Corey Cutler, MD MPH, FRCPC, Rizwan Romee, MD PhD

Blood (2019) 134 (Supplement_1): 4486.

https://doi.org/10.1182/blood-2019-121659

Published: 2019

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Anneke D. van Dijk, BS, Peter P. Ruvolo, PhD, Fieke W Hoff, BSc, Yihua Qiu, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Anders E. Kolb, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, Eveline S. de Bont, MD PhD, Sophia W.M. Bruggeman, PhD, Terzah M Horton, MD PhD, Steven M. Kornblau, MD

Blood (2019) 134 (Supplement_1): 2676.

https://doi.org/10.1182/blood-2019-128579

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Disease Modeling of Severe Congenital Neutropenia Using CRISPR/Cas9 Gene Correction or Knockout of ELANE in Patients Derived Induced Pluripotent Stem Cells

CRISPR/Cas9 Mediated ELANE Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensible Granulocyte Protease?

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Role of Acute Myeloid Leukemia Derived-Extracellular Vesicles in Dysregulating Normal Hematopoiesis

Night Transplantation and Catecholamine Exposure Accelerates In Vivo Leukemia Development By Enhancing Bone Marrow Homing Capacity in Leukemic Cells

Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Combination of a Cyclophosphamide-Total Body Irradiation Conditioning Regimen and Tacrolimus Plus Mycophenolate Mofetil for Gvhd Prophylaxis Is Associated with Higher HHV-6 Encephalitis Incidence after Cord Blood Transplantation

Are We Choosing Mobilization Regimens for Autologous Stem Cell Transplantation in Multiple Myeloma Wisely?: A Single Centre Comparison of GCSF+/-Plerixafor Vs Cyclophosphamide/GCSF+/- Plerixafor

Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations

Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor

Protein Arginine Methyltransferase 1 Is Required for Maintenance of Normal Adult Hematopoiesis

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology